SAN DIEGO--(BUSINESS WIRE)--LATITUDE Pharmaceuticals, Inc. (LPI), a San Diego-based drug formulation developer, announced today that it has initiated two new collaboration programs for its Phospholipid Gel (PG) Depot drug delivery platform. The programs are designed to provide prolonged and peak-free pharmacokinetic profiles for 3 and 7 days following a subcutaneous injection for an antibiotic and a protein drug, respectively. The new studies bring the total to seven feasibility/license agreements that are applying the PG Depot to deliver small molecules, peptides, and proteins for pain, metabolic disease, anti-bacterial, and cardiovascular applications.
